Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed ...

The Shocking Truth" How did Zantac, once the world's most popular drug for acid reflux and heartburn, turn into a toxic ...

葛兰素史克 在美国州法院Zantac案件中达成高达22亿美元的和解协议。 葛兰素史克公司周三表示，已与10家原告公司达成协议，这些公司占美国州法院 ...

Zantac于1983年首次获得美国监管机构的批准，并于1988年成为世界上最畅销的药物，也是首批年销售额超过10亿美元的药物之一。这种药物在不同时期由 ...

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...

An over-the-counter medication sold today as Zantac 360 by Sanofi has a different active ingredient from the withdrawn versions of Zantac and has not raised questions about a cancer link.

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.